New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Subscribe To Our Newsletter & Stay Updated
